Associated Papers
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer.
Cao J et al.
Journal of Chemotherapy (florence, Italy), 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
The Role of Pharmacogenetic Biomarkers in Pain.
Martin da Silva I et al.
Biomedicines, 2025
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants.
Babaev D et al.
Frontiers in Systems Biology, 2025
Distribution of the cytochrome P450 *alleles for CYP2C9 and CYP2C19 in a cohort of the Danish Blood Donor Study determined by using the Illumina Infinium Global Screening Array.
Jørgensen S et al.
Basic & Clinical Pharmacology & Toxicology, 2024
Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes.
Mouhrach I et al.
Pharmacogenomics and Personalized Medicine, 2023
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC et al.
Molecular Diagnosis & Therapy, 2021
HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project.
Hikino K et al.
Clinical Pharmacology and Therapeutics, 2020
Role of Genetic Variations in the Hepatic Handling of Drugs.
Marin JJG et al.
International Journal of Molecular Sciences, 2020
Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I et al.
International Journal of Legal Medicine, 2020
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A et al.
European Review for Medical and Pharmacological Sciences, 2020
CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW et al.
Journal of Clinical Pharmacy and Therapeutics, 2019
Personalized rosuvastatin therapy in problem patients with partial statin intolerance.
Shek AB et al.
Archives of Medical Sciences. Atherosclerotic Diseases, 2018
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan.
Mirzaev KB et al.
Genetic Testing and Molecular Biomarkers, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
Yin SJ et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations.
Sychev DA et al.
Pharmacogenomics and Personalized Medicine, 2017
Harnessing Knowledge on Very Important Pharmacogenes CYP2C9 and CYP2C19 Variation for Precision Medicine in Resource-Limited Global Conflict Zones.
Barlas İÖ et al.
Omics : a Journal of Integrative Biology, 2016
[POLYMORPHISM OF CYP2C9 GENE AND RISK OF HEPATOTOXICITY DEVELOPMENT DURING ANTIRETROVIRAL THERAPY.]
Kurbat MN et al.
Eksperimental'naia I Klinicheskaia Farmakologiia, 2016
Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.
Abdelhedi R et al.
Journal of Genetics, 2015
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E et al.
Thrombosis Research, 2014
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.
Nahar R et al.
Thrombosis Research, 2013
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2013
Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Archives of Toxicology, 2013
CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.
Musumba CO et al.
Clinical Pharmacology and Therapeutics, 2013
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Seredina TA et al.
Bmc Medical Genetics, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay.
Wang H et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2011
The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement.
Zhong SL et al.
European Journal of Clinical Pharmacology, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Afsar NA et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
Bozina N et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2009
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Zanger UM et al.
Analytical and Bioanalytical Chemistry, 2008
Novel CYP2C9 promoter variants and assessment of their impact on gene expression.
Kramer MA et al.
Molecular Pharmacology, 2008
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.
Flockhart DA et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2008
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Zandvliet AS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
Lötsch J et al.
Clinical Pharmacology and Therapeutics, 2006
The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH et al.
Journal of Human Genetics, 2006
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
DeLozier TC et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
[Implications of pharmacogenetics in every-day practice].
Gerloff T et al.
Der Internist, 2005
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F et al.
Clinical Pharmacology and Therapeutics, 2004
Discovery of new potentially defective alleles of human CYP2C9.
Blaisdell J et al.
Pharmacogenetics, 2004
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K et al.
Arthritis and Rheumatism, 2004